Enhanced Participant Experience: DCTs provide more options for patients to participate in trials through a combination of technology and services. This improved patient experience increases both trial participation and retention.
Business Continuity: DCTs were a critical countermeasure to maintain trial conduct during the COVID-19 pandemic and will remain an important tool for business continuity in an unpredictable global environment.
Enhanced Participant Access: DCTs provide a more convenient and comfortable environment for patients, allowing them to participate in clinical trials from home or nearby locations.
Sustainability: As more sponsors include sustainable clinical trials as part of their ESG and corporate social responsibility commitment, DCTs will be an important tool in reducing the impact of travel and associated burden on the planet.
Support Increased Diversity: By removing barriers to trial access, DCTs support the opportunity for a more diverse range of participants, which ultimately leads to more inclusive and representative research outcomes.
